Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | 3004333 | PO / MO |
Patient took first dose on 24-Jul-2025, second dose on 25-Jul-2025 and third dose on 27-Jul-2025; Case reference number US-BN-2025-001324 is a spontaneous case initially received from other healthcare professional via Communications (reference number: USBAV25-1828) on 28-Jul-2025 and concerns a 13-year-old female patient. The patient's had no medical history noted. The patient's concomitant medication details were not provided. On 24-Jul-2025, the patient received the first dose of Vivotif (batch number: 3004333) at unknown dose, orally for pre travel. On 25-Jul-2025, the patient received the second dose of Vivotif (batch number: 3004333) at unknown dose, orally. (explicitly coded as 'Inappropriate schedule of product administration') On 27-Jul-2025, the patient received the third dose of Vivotif (batch number: 3004333) at unknown dose, orally. (explicitly coded as 'Inappropriate schedule of product administration') At the time of initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Additional information received from pharmacist via communications on 28-Jul-2025 included reporter details, patient details, Vivotif dosing details and new reference number (USBAV25-1837); Reporter's Comments: A 13-year-old female patient received the second dose of Vivotif for pre travel on the day 1 after the first dose, and the third dose on the day 3 after the first dose, which is considered as inappropriate schedule of product administration. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient had no medical history noted, and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 13-year-old female patient received the second dose of Vivotif for pre travel on the day 1 after the first dose, and the third dose on the day 3 after the first dose, which is considered as inappropriate schedule of product administration. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient had no medical history noted, and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None